跳至主要内容
临床试验/JPRN-C000000210
JPRN-C000000210已完成2 期

Clinical trial of postoperative adjuvant chemotherapy with carboplatin/paclitaxel according to the results of collagen gel droplet embedded culture drug sensitivity test (CD-DST) in completely resected non-small-cell lung cancer - Postoperative adjuvant chemotherapy according to the results of drug sensitivity test in non-small-cell lung cancer

Department of General Thoracic Surgery, Osaka University Graduate School of Medicine0 个研究点目标入组 92 人开始时间: 2005年9月15日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
92

研究概览

简要总结

The chemosensitivity to carboplatin and/or paclitaxel was 76%. The 5-year OS rates were 71, 73, and 75% for all, CD-DST success, and chemosensitive patients, respectively. The 5-year DFS and OS rates of the chemosensitive patients who completed adjuvant chemotherapy using carboplatin/paclitaxel were 68 and 82%, respectively. The 5-year DFS and OS rates of the patients with stage II-IIIA chemosensitive NSCLC were 58 and 75%, respectively.

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1, Heart diseases required treatment. 2, Myocardial infarction within 6 months. 3, Liver cirrhosis. 4, Symptomatic interstitial pneumonia or pulmonary fibrosis proven in the chest X-ray. 5, Active bowel hemorrhage required repeated transfusion. 6, Uncontrollable diabetes mellitus. 7, Ileus or subileus. 8, Active infection. 9, Peripheral neuropathy. 10, Psychological disorder required medication. 11, Drug allergy against cremophor EL(polyoxethylated castor oil). 12, During pregnancy or lactation. 13, Inadequate condition diagnosed by the primary physician.

研究者

发起方
Department of General Thoracic Surgery, Osaka University Graduate School of Medicine

相似试验